Research Paper Volume 15, Issue 22 pp 12890—12906
TJP3 promotes T cell immunity escape and chemoresistance in breast cancer: a comprehensive analysis of anoikis-based prognosis prediction and drug sensitivity stratification
Figure 7. TJP3 is a pivotal hubgene in regulating drug tolerance. (A) Importance analysis in XGboost, in which SFN, TJP3, TACSTD2, GGT6, TMC4, PRSS8, S100A14, SH2D3A, GYLTL1B, and ELF3. (B) K-M analysis of S100A14, SH2D3A, TJP3, and TMC4 in regulating prognosis. (C) The roles of TJP3 in regulating prognosis in TNBC cohort, (D) chemotherapy cohort, and (E) endocrinotherapy cohort. (F) TJP3 expression in pan-cancer and adjacent tissues. (G) The expression level of TJP3 in adjacent tissues and breast cancer tissues (data from THPA). (H) Statistical results of TJP3 expression in THPA cohort. (I) TJP3 expression level in TNBC and corresponding adjacent tissues. (J) TJP3 expression level in IDC and corresponding adjacent tissues, data from GSE10780. (K) The correlation between the expression of TJP3 and drug scores (EPI, CTX, DTX, PTX, DDP, GEM, 5-Fu, NVB, Olaparib, TAM). *p < 0.05, **p < 0.01, ***p < 0.001.